Vilin Bio Med — 360° view

Vilin Bio Med, a company in the Pharmaceuticals industry, reported revenue of ₹33 crore and net profit of ₹1.78 crore for the March 2026 quarter.

Vilin Bio Med (NSE: VILINBIO-SM) closed at ₹52.75 on 20 Nov 2026. Its market capitalisation is ₹80 crore and it trades at 41.7 times earnings.

Share price
₹52.75 (20 Nov 2026)
Market cap
₹80 Cr (20 Nov 2026)
P/E
41.68 (20 Nov 2026)
Revenue
₹33 Cr (March 2026 quarter)
Net profit
₹2 Cr (March 2026 quarter)
ROCE
10.8% (FY26)
ROE
7.51% (FY26)
Book value
₹18.6 (FY26)
Dividend yield
0.00% (last 12 months to 20 Nov 2026)
52-week high / low
₹60.95 / ₹38.60 (20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: VILINBIO-SM

Incorporated in 2005, Vilin Bio Med Ltd is in the business of manufacturing and selling of pharmaceutical products

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.